The investment case for UnitedHealth Group Inc. (NYSE:UNH) rests on how management can restore the company’s profitability margins and reignite its topline expansion to justify an earnings turnaround, which the current forward P/E multiple already assumes. The overall profile for UnitedHealth appears mixed yet highly intriguing. Despite its cash flow strength, flat revenue growth and compressed margins warrant some caution, as the stock has underperformed relative to the broader market. Here is what investors need to know about UnitedHealth’s turnaround plans for its Florida WellMed clinics.
UnitedHealth (UNH) made our list of the 10 Best Healthcare Stocks to Buy According to Hedge Funds. But is it the #1 pick, or are hedge funds favoring other healthcare giants?
Likoper/Shutterstock.com
Lagging the Broader Market
The stock traded at $378.58 by October 5 closing, pushing this health insurance giant’s market capitalization to $334.76 billion. It has gained 14.1% so far in 2026, a solid showing that nonetheless masks a more complicated picture over the longer window. Over the last 52 weeks, UnitedHealth’s gain of 4.10% lags the S&P 500’s 15.78% by a notable margin.
The management is looking to turn things around by actively consolidating its portfolio. It plans to streamline the underlying units by stripping away some of the non-core assets. This would help manage increasing medical expenses and improve margins. Recently, the company sold an ownership interest in some Florida WellMed clinics while retaining an interest in the operations to the private equity firm, TPG. The move would support a turnaround for Optum Health, as management is targeting margins of around 2%, 4% and 6% for 2026 through 2028.
Weighing Cash Flow Strength Against Flat Revenue Growth
Total revenue for the last twelve months came in at $450.53 billion, which leads to an enormous base. However, the topline growth of 0.40% during the second quarter of fiscal 2026 was not very encouraging. Profitability margins are thin as the company delivered 5.35% operating margin on a trailing basis, while net margin stood at 3.14%.
These figures are weaker compared to the company’s historical performance. One could argue that managed care space generally does not offer too high margins. But in UnitedHealth’s case, the compression points to cost pressures that investors have been watching closely. Despite that, the overall return on equity is in mid-teens, precisely 14.15%. Operating cash flows were also impressive, reaching $27 billion over the trailing twelve months. The company generated $24.3 billion in levered free cash flow. Those figures give the company ample capacity to service debt, fund dividends and invest in the business. Is UnitedHealth trying to make patient care more accessible? See how its insurance unit is removing prior-authorization requirements from a range of services.
Institutional Sentiment
Based on data tracked across 1,000+ hedge funds by Insider Monkey, institutional sentiment toward the company remains strong. According to 13F filing data, number of smart-money managers with long-term exposure in the stock has been going up. A total of 143 hedge funds held positions by the end of Q2 2026, compared to 130 in Q1 2026.
BlackRock is the largest institutional stakeholder, as per Yahoo Finance database, holding 76.86 million shares as of June 30. This amounts to 8.56% of outstanding shares. Other notable institutional investors include Vanguard Capital Management and State Street, holding 6.61% and 5.08% of outstanding shares respectively.
Verdict
A short float of just 1.64% and short ratio of 2.78 highlight very nominal appetite among speculators to bet against the stock. Despite the operational challenges, bears do not seem to be piling in. The stock is currently trading at a trailing P/E multiple of 23.97x, and a forward multiple of 16.58x. That wide gap shows that analysts are projecting a meaningful rebound in earnings from the recently depressed levels. A forward multiple in mid-teens, especially for a company of this scale, is far from demanding. However, it still offers little room for disappointment if the projected recovery stalls. The WellMed restructuring could support UnitedHealth’s margin recovery, but successful execution and sustained profitability improvements will be essential to justify further stock upside.
While we acknowledge the risk and potential of UNH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than UNH and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: Willis Lease Finance (WLFC) Bets on Malaysia for Next Phase of Global Expansion and What Lies Ahead for Marcus & Millichap (MMI) Following These Multifamily Asset Sales?.
Hedge Fund Resource Center